FDA regs are not the only drivers of R&D costs

12/20/2012 | Forbes

FDA regulations are often blamed for the high cost of drug development, but drugmakers' business decisions may be the real culprits, writes Bernard Munos. FDA approval requires two successful Phase III trials, but drugmakers performed dozens of trials in support of blockbusters, whether to broaden the indication or in support of marketing, Munos writes. Moreover, the high failure rate of pre-approval Phase III trials seems to indicate that executives are pushing mediocre drug candidates through the pipeline, he writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID